Aviva PLC, a multinational insurance company based in London, has disclosed that it has lowered its stake in Molina Healthcare, Inc. by 28.6% during the last quarter of 2020. As of December 31, the British insurer held 10,426 shares in Molina Healthcare worth $3,443,000 after selling 4,175 shares.
Molina Healthcare is a California-based health care provider with four segments: Medicaid, Medicare, Marketplace and Other. Founded by C. David Molina in 1980, the company boasts a market capitalization of $16.61 billion and trades on the New York Stock Exchange under the ticker symbol MOH.
Despite having consistent earnings over the years and strong fundamentals backed up by a quick ratio of 1.47 and debt-to-equity ratio of 0.72, share prices of Molina Healthcare have been volatile within the past 52 weeks. The investment community’s views on this stock escalated from low valuations at $249.78 to peak prices at $374.00 per share within that period.
Currently trading at $284.83 per share upon opening on February 5th as per data from NYSE real-time data service MarketWatch.com; investors must take a closer look on these trends for their portfolios’ projected returns before making any critical decisions regarding investing in MOH.
Shares will soon be hitting their ex-dividend date this month as announced publicly by Dividend.com on January 25th (February 12th), making stockholders eligible to receive quarterly dividends from last year’s Q4 net income report: an exciting opportunity for passive income investors looking towards putting their money to work along with owning a percentage stake in an accredited healthcare services provider.
Investing is not only about gaining monetary success but also requires careful decision-making processes based on extensive research of both markets and individual companies to optimize returns while minimizing risks associated with investments. In the case of Molina Healthcare, the company’s ability to continue its growth trajectory may lead to increased investor interest and expert recommendation for inclusion within a well-diversified portfolio over time.
Financial Health
Neutral
Debt to equity ratio:
Price to earnings ratio:
Price to book ratio:
Show more
Social Sentiments
We did not find social sentiment data for this stock
Analyst Ratings
There are no analysts data to display
Investors remain interested in Molina Healthcare despite criticisms
Molina Healthcare, a leading healthcare provider in the United States, has recently caught the attention of several institutional investors and hedge funds. Among these investors are Raymond James Financial Services Advisors Inc., which increased its stake in Molina Healthcare by 5.7% during Q1 this year, bringing its shares up to a value of $551,000 after purchasing an additional 89 shares during the period.
Similarly, German investment firm Allianz Asset Management GmbH lifted its position in Molina Healthcare by a whopping 496.1% during the same quarter, acquiring 9,599 more shares valued at $3,848,000 and indicating strong investor confidence in the company’s future performance.
Other significant buyers include Prudential PLC and Cetera Investment Advisers who have bought new positions amounting to over $422,000 and $432,000 respectively. Meanwhile, Mackay Shields LLC acquired a new position valued at approximately $2,814,000.
All these investments demonstrate that institutional investors continue to be highly interested in investing their funds into companies such as Molina Healthcare. As of today, institutional investors and hedge funds hold 94.25% of all outstanding stocks of the company.
Despite some analyst criticisms concerning low ratings for Molina Healthcare stock on Bloomberg.com over recent months – ranging from sell to moderate buy ratings – there still appears to be a consensus among experts that this is generally looking like a positive time for the firm given their strong Q1 earnings report for this year. Molina over-performed compared to analysts’ estimates with earnings per share (EPS) including $5.81; higher than predicted estimates ($5.13). While revenue didn’t quite meet expectations ($8.15 billion versus projections of $8.31 billion), they did increase sales by +4.9% YoY.
However it’s not wholly positive news because one insider selling off five thousand dollars (approx.) worth of shares in the same quarter has sparked some concerns among speculators. Despite this insider selling, analysts continue to be bullish about Molina Healthcare – rating it as a potentially growing Moderate Buy.
In conclusion, it seems that despite any potential red flags warning investors away from this stock, Molina Healthcare remains one of the top players in healthcare services especially thanks to their accounts always showing clear profits and returns to shareholders. It may be worth following the movements and performance of this controversial stock over the next few months to offer greater insights into its future potential.